Mutations within the rplD gene of linezolid-nonsusceptible Streptococcus pneumoniae strains isolated in the United States

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 2459-2462

  Dong, W ^a   Chochua, S ^a   McGee, L ^b   Jackson, D ^b   Klugman, K P ^a   Vidal, J E ^a  

^a EMORY UNIVERSITY   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CHLORAMPHENICOL; CLINDAMYCIN; ERYTHROMYCIN; LINEZOLID; PENICILLIN DERIVATIVE; RIBOSOME PROTEIN; RIBOSOME RNA; TETRACYCLINE; VANCOMYCIN;

ALLELE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATION; GENE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ACETAMIDES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; MUTATION; OXAZOLIDINONES; RNA, RIBOSOMAL, 23S; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 84896916493     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02630-13     Document Type: Article

References (32)

1. Vinh DC, Rubinstein E. 2009. Linezolid: a review of safety and tolerability. J. Infect. 59(Suppl 1):S59-S74. http://dx.doi.org/10.1016/S0163- 4453(09)60009-8.
2. Bozdogan B, Appelbaum PC. 2004. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int. J. Antimicrob. Agents 23:113-119. http://dx.doi.org/10.1016/j.ijantimicag.2003.11.003.
3. Livermore DM. 2003. Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother. 51(Suppl 2):ii9-ii16. http://dx.doi.org/10. 1093/jac/dkg249. (Pubitemid 36622107)
4. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. 1998. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother. 42:3251-3255. (Pubitemid 28553749)
5. Draghi DC, Sheehan DJ, Hogan P, Sahm DF. 2005. In vitro activity of linezolid against key Gram-positive organisms isolated in the United States: results of the LEADER 2004 Surveillance Program. Antimicrob. Agents Chemother. 49:5024-5032. http://dx.doi.org/10.1128/AAC.49.12.5024-5032.2005. (Pubitemid 41778916)
6. Farrell DJ, Mendes RE, Ross JE, Jones RN. 2009. Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagn. Microbiol. Infect. Dis. 65:392-403. http://dx.doi.org/10.1016/j.diagmicrobio.2009.10.011.
7. Jones RN, Fritsche TR, Sader HS, Ross JE. 2007. LEADER Surveillance Program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn. Microbiol. Infect. Dis. 59:309-317. http://dx.doi.org/10.1016/j.diagmicrobio.2007.06.004. (Pubitemid 350016703)
8. Jones RN, Ross JE, Castanheira M, Mendes RE. 2008. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn. Microbiol. Infect. Dis. 62:416-426. http://dx.doi.org/10.1016/j.diagmicrobio. 2008.10.010.
9. Flamm RK, Mendes RE, Ross JE, Sader HS, Jones RN. 2013. Linezolid surveillance results for the United States: LEADER Surveillance Program 2011. Antimicrob. Agents Chemother. 57:1077-1081. http://dx.doi.org/10.1128/AAC.02112- 12.
10. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing - approved standard M100-S23, 23rd ed. CLSI, Wayne, PA.
11. Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN. 2008. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 52:2244-2246. http://dx.doi.org/10.1128/AAC.00231-08. (Pubitemid 351758569)
12. Long KS, Vester B. 2012. Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrob. Agents Chemother. 56:603-612. http://dx.doi.org/10.1128/AAC.05702-11.
13. Marshall SH, Donskey CJ, Hutton-Thomas R, Salata RA, Rice LB. 2002. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob. Agents Chemother. 46:3334-3336. http://dx.doi.org/10.1128/ AAC.46.10.3334-3336.2002.
14. Besier S, Ludwig A, Zander J, Brade V, Wichelhaus TA. 2008. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrob. Agents Chemother. 52:1570-1572. http://dx.doi.org/10.1128/AAC.01098-07. (Pubitemid 351522039)
15. Sorlozano A, Gutierrez J, Martinez T, Yuste ME, Perez-Lopez JA, Vindel A, Guillen J, Boquete T. 2010. Detection of new mutations conferring resistance to linezolid in glycopeptide-intermediate susceptibility Staphylococcus hominis subspecies hominis circulating in an intensive care unit. Eur. J. Clin. Microbiol. Infect. Dis. 29:73-80. http://dx.doi.org/10.1007/s10096-009-0823-4.
16. Farrell DJ, Morrissey I, Bakker S, Buckridge S, Felmingham D. 2004. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations. Antimicrob. Agents Chemother. 48:3169-3171. http://dx.doi.org/10. 1128/AAC.48.8.3169-3171.2004. (Pubitemid 38989196)
17. Wong A, Reddy SP, Smyth DS, Aguero-Rosenfeld ME, Sakoulas G, Robinson DA. 2010. Polyphyletic emergence of linezolid-resistant staphylococci in the United States. Antimicrob. Agents Chemother. 54:742-748. http://dx.doi.org/10.1128/ AAC.00621-09.
18. Kehrenberg C, Schwarz S, Jacobsen L, Hansen LH, Vester B. 2005. A new mechanism for chloramphenicol, florfenicol and clindamycin resistance: methylation of 23S ribosomal RNA at A2503. Mol. Microbiol. 57: 1064-1073. http://dx.doi.org/10.1111/j.1365-2958.2005.04754.x. (Pubitemid 41139866)
19. Toh SM, Xiong L, Arias CA, Villegas MV, Lolans K, Quinn J, Mankin AS. 2007. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol. Microbiol. 64:1506-1514. http://dx.doi.org/10.1111/j. 1365-2958.2007.05744.x. (Pubitemid 46889900)
20. Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Pelaez B, Andrade R, de la Torre MA, Fereres J, Sanchez-Garcia M. 2010. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin. Infect. Dis. 50:821-825. http://dx.doi.org/10.1086/650574.
21. Kehrenberg C, Aarestrup FM, Schwarz S. 2007. IS21-558 insertion sequences are involved in the mobility of the multiresistance gene cfr. Antimicrob. Agents Chemother. 51:483-487. http://dx.doi.org/10.1128/AAC.01340-06. (Pubitemid 46185264)
22. Wang Y, Li D, Song L, Liu Y, He T, Liu H, Wu C, Schwarz S, Shen J. 2013. First report of the multiresistance gene cfr in Streptococcus suis. Antimicrob. Agents Chemother. 57:4061-4063. http://dx.doi.org/10.1128/AAC.00713-13.
23. Wolter N, Smith AM, Farrell DJ, Schaffner W, Moore M, Whitney CG, Jorgensen JH, Klugman KP. 2005. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob. Agents Chemother. 49:3554-3557. http://dx.doi.org/10.1128/AAC.49.8. 3554-3557.2005. (Pubitemid 41060618)
24. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically - approved standard M7-A8, 8th ed. CLSI, Wayne, PA.
25. Tait-Kamradt A, Davies T, Cronan M, Jacobs MR, Appelbaum PC, Sutcliffe J. 2000. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob. Agents Chemother. 44:2118-2125. http://dx.doi.org/10.1128/AAC.44.8.2118-2125.2000. (Pubitemid 30484435)
26. Mendes RE, Deshpande LM, Farrell DJ, Spanu T, Fadda G, Jones RN. 2010. Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. J. Antimicrob. Chemother. 65:2329-2335. http://dx.doi.org/10.1093/jac/dkq331.
27. Miller K, Dunsmore CJ, Fishwick CW, Chopra I. 2008. Linezolid and tiamulin cross-resistance in Staphylococcus aureus mediated by point mutations in the peptidyl transferase center. Antimicrob. Agents Chemother. 52:1737-1742. http://dx.doi.org/10.1128/AAC.01015-07. (Pubitemid 351614667)
28. Kehrenberg C, Schwarz S. 2006. Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates. Antimicrob. Agents Chemother. 50:1156-1163. http://dx.doi.org/10.1128/AAC.50.4. 1156-1163.2006.
29. Hoskins J, Alborn WE, Jr, Arnold J, Blaszczak LC, Burgett S, DeHoff BS, Estrem ST, Fritz L, Fu DJ, Fuller W, Geringer C, Gilmour R, Glass JS, Khoja H, Kraft AR, Lagace RE, LeBlanc DJ, Lee LN, Lefkowitz EJ, Lu J, Matsushima P, McAhren SM, McHenney M, McLeaster K, Mundy CW, Nicas TI, Norris FH, O'Gara M, Peery RB, Robertson GT, Rockey P, Sun PM, Winkler ME, Yang Y, Young-Bellido M, Zhao G, Zook CA, Baltz RH, Jaskunas SR, Rosteck PR, Jr, Skatrud PL, Glass JI. 2001. Genome of the bacterium Streptococcus pneumoniae strain R6. J. Bacteriol. 183:5709-5717. http://dx.doi.org/10.1128/JB.183.19.5709-5717.2001. (Pubitemid 32898618)
30. Feng J, Lupien A, Gingras H, Wasserscheid J, Dewar K, Legare D, Ouellette M. 2009. Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 19:1214-1223. http://dx.doi.org/10.1101/gr.089342.108.
31. Biedenbach DJ, Farrell DJ, Mendes RE, Ross JE, Jones RN. 2010. Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox Annual Appraisal of Potency and Spectrum program. Diagn. Microbiol. Infect. Dis. 68:459-467. http://dx.doi.org/10.1016/j. diagmicrobio.2010.09.018.
32. Klugman KP, Low DE, Metlay J, Pechere JC, Weiss K. 2004. Community-acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities. Int. J. Antimicrob. Agents 24:411-422. http://dx.doi.org/10.1016/j.ijantimicag.2004.08.006. (Pubitemid 39425150)